Long-term toxicities and quality of life of cancer survivors treated with immunotherapy

Status: Recruiting

Eligibility Criteria
Sex: Male or Female
Age: 18 Years and over

Inclusion Criteria:
Individuals diagnosed with cancer and treated with immunotherapies within the MHealth Fairview system

Conditions & Interventions
Conditions:
Cancer
Keywords:
immunotherapy, Clinics and Surgery Center (CSC)

More Information
Description: Immunotherapies, such as immune checkpoint inhibitors, have greatly improved survival for many cancers and are now approved for over half of all cancer patients. However, many patients receiving immunotherapy experience Grade 3 and 4 toxicities, termed immune-related adverse events (IRAEs) which cause frequent hospitalizations, emergency department visits, impaired health-related quality of life (QOL) and often discontinuation of therapy. While clinical trials of immunotherapeutic drugs have reported on IRAEs over short time-periods, the real-life and long-term frequencies of and experiences with IRAEs outside of clinical trials, and the general experience of taking immunotherapies long-term remain unknown. The goal of this protocol is to build a prospective cohort study of cancer survivors who receive immunotherapies.

Contact(s): Maria Pecoraro - pecor011@umn.edu
Principal Investigator: Rachel Vogel
IRB Number: STUDY00016320
System ID: STUDY00016320

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.